Related Experiment Videos
[Apolipoproteins A and B in cerebrovascular diseases]
Insights
Determining apolipoproteins A and B offers a superior method for assessing cerebrovascular disease risk compared to traditional lipid profiles. The apolipoprotein L A/B quotient is a more sensitive indicator for identifying individuals at risk, even with normal cholesterol levels.
Area of Science:
- Biochemistry
- Clinical Medicine
- Cardiovascular Research
Context:
- Cerebrovascular disease (CVD) poses a significant health burden.
- Current risk assessment often relies on lipid profiles like HDL, LDL, and VLDL.
- These traditional markers may not fully capture an individual's risk profile.
Purpose:
- To evaluate the diagnostic value of apolipoproteins A and B, and their quotient (APO-L A/B), in assessing cerebrovascular disease risk.
- To compare the efficacy of apolipoprotein determination against conventional lipid measurements.
Summary:
- The study found that the apolipoprotein L A/B quotient is a more sensitive indicator of cerebrovascular disease risk than standard cholesterol levels.
- A reduced APO-L A/B quotient (less than 1.75) was identified in 74% of CVD patients, including those with normal cholesterol.
- Apolipoprotein determination is proposed as an advancement over traditional HDL, LDL, and VLDL analysis for risk stratification.
Impact:
- This research suggests a more accurate method for identifying individuals at risk of cerebrovascular disease.
- Implementing apolipoprotein testing could lead to earlier and more effective interventions for arteriosclerotic disease prevention.
- The findings advocate for a shift in diagnostic practices towards apolipoprotein profiling for enhanced risk assessment.
Abstract:
The present study has proved unequivocally the value of determining apolipoproteins A and B and the APO-L A/B quotient for establishing the risk for cerebrovascular disease. The determination of apolipoproteins should be preferred to the determination of HDL, LDL and VLDL, which has been practised so far. While only 30% of a group of 88 patients suffering from cerebrovascular disease had serum cholesterol levels of more than 250 mg/dl and approx. 57% showed HDL values below 40 mg/dl, a reduced APO-L A/B relation (less than 1.75) was demonstrated in 74%. A reduced APO-L A/B quotient was also observed in more than 70% of 62 CVD patients whose cholesterol level was within the range of normal. Determination of apolipoproteins may, therefore, be regarded as further progress in risk factor diagnostic of arteriosclerotic disease.